Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

Bristol-Myers Squibb to Take Part in Citi 2013 Global Health Care Conference

Business Wire February 19, 2013

Earnings Help Fuel S&P 500 Index Rally -- S&P 500 Index Tops 1500 Mark for the First Time in 5 Years

Marketwired February 19, 2013

Leading Pharmaceutical Companies Mid-day Trading with Mixed Results and also New Patent News Announced for Crown Marketing

PR Newswire February 14, 2013

Bristol-Myers Squibb Appoints Ann Powell Judge Senior Vice President, Human Resources

Business Wire February 14, 2013

Bristol-Myers Squibb Enters a Collaboration Agreement for Several Over-the-Counter Medicines with Reckitt Benckiser Group plc

Business Wire February 12, 2013

Should Recent Insider Selling on BMY, GOOG, UNM and MDC Matter to You?

Marketwired February 11, 2013

Bristol-Myers Squibb to Take Part in Leerink Swann Global Health Care Conference

Business Wire February 6, 2013

Free Research Report on BP Plc, Bristol-Myers Squibb Co., Aetna, Inc. and Analog Devices, Inc.

Marketwired February 4, 2013

Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2012 Financial Results

Business Wire January 24, 2013

Bristol-Myers Squibb Appoints Mike Burgess M.D., Ph.D. Senior Vice President, Discovery Medicine and Clinical Pharmacology

Business Wire January 17, 2013

ERBITUX® in combination with chemotherapy approved in Canada as initial treatment of patients with metastatic colorectal cancer

Canada NewsWire January 14, 2013

OPKO Health Expands Collaboration with Bristol-Myers Squibb

Business Wire January 14, 2013

Perfect Trade Setups, How to Play CELG, NVS, GSK and BMY

Marketwired January 14, 2013

The Real Story Behind ISIS, BIIB, NWBO and BMY

Marketwired January 11, 2013

Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2012 on January 24

Business Wire January 4, 2013

Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference

Business Wire January 3, 2013

S&P 500 Index Posts Best Year Since 2009 -- Bristol Myers Squibb and Johnson & Johnson Receive FDA Approvals

Marketwired January 2, 2013

U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

Business Wire January 2, 2013

Bristol-Myers Squibb and Pfizer Announce U.S. FDA Approval of ELIQUIS® (apixaban)

Business Wire December 28, 2012

ELIQUIS® (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation

Business Wire December 26, 2012